Comparing Single, Dual, and Triple Gut Hormone Agonists Reveals Important Differences in Receptor Signaling
Dual agonist LY3298176 (tirzepatide) and triple agonists showed biased signaling toward ERK1/2 phosphorylation over cAMP at both GIP and GLP-1 receptors, which may influence clinical response diversity.
Quick Facts
What This Study Found
LY3298176 (tirzepatide) is biased toward pERK1/2 relative to cAMP at both GIPR and GLP-1R. The triple agonist showed bias toward pERK1/2 relative to β-arrestin2 recruitment at GLP-1R. Mono-agonists Pro3GIP and Lys3GIP are biased toward pERK1/2 at GIPR.
Key Numbers
Compared mono-, dual-, and tri-agonist profiles at GIPR, GLP-1R, and glucagon receptors.
How They Did This
Pharmacological characterization using HEK293 cells recombinantly expressing human GIPR or GLP-1R. Measured cAMP accumulation, ERK1/2 phosphorylation, and β-arrestin2 recruitment to determine signaling bias compared to endogenous ligands.
Why This Research Matters
Understanding biased agonism at gut hormone receptors explains why structurally similar drugs can have different clinical effects on weight loss, blood sugar, and side effects. This knowledge could guide design of next-generation obesity and diabetes drugs.
The Bigger Picture
The GLP-1 receptor agonist market has exploded with drugs like semaglutide and tirzepatide. This pharmacological deep-dive reveals that these drugs aren't simply 'turning on' receptors — they're activating them in nuanced ways that produce different downstream effects, potentially explaining the clinical superiority of dual agonists like tirzepatide.
What This Study Doesn't Tell Us
HEK293 cell overexpression system may not fully replicate signaling in native tissues. Biased agonism observed in vitro may not directly predict clinical outcomes. The relationship between ERK1/2 bias and therapeutic efficacy needs clinical validation.
Questions This Raises
- ?Does tirzepatide's ERK1/2 signaling bias explain its superior weight loss compared to GLP-1 mono-agonists?
- ?Can receptor signaling bias be engineered into next-generation dual/triple agonists for optimal clinical effects?
- ?How does biased agonism at gut hormone receptors affect gastrointestinal side effects?
Trust & Context
- Key Stat:
- Biased agonism tirzepatide preferentially activates ERK1/2 over cAMP at both GIP and GLP-1 receptors
- Evidence Grade:
- Rigorous in vitro pharmacological characterization with proper controls against endogenous ligands. Foundational receptor science but clinical significance of biased agonism needs further study.
- Study Age:
- Published in 2020, before tirzepatide (Mounjaro/Zepbound) received FDA approval. The biased agonism findings add pharmacological depth to understanding this blockbuster drug.
- Original Title:
- Pharmacological characterization of mono-, dual- and tri-peptidic agonists at GIP and GLP-1 receptors.
- Published In:
- Biochemical pharmacology, 177, 114001 (2020)
- Authors:
- Yuliantie, Elita, Darbalaei, Sanaz(2), Dai, Antao(2), Zhao, Peishen, Yang, Dehua, Sexton, Patrick M, Wang, Ming-Wei, Wootten, Denise
- Database ID:
- RPEP-05228
Evidence Hierarchy
Frequently Asked Questions
What is biased agonism?
When a drug activates a receptor, it can trigger multiple downstream pathways. Biased agonism means the drug preferentially activates some pathways over others, potentially producing different therapeutic effects and side effect profiles.
What is LY3298176?
LY3298176 is the research name for tirzepatide, now marketed as Mounjaro (for diabetes) and Zepbound (for weight loss). It's a dual GIP/GLP-1 receptor agonist that has shown superior weight loss compared to GLP-1-only drugs.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05228APA
Yuliantie, Elita; Darbalaei, Sanaz; Dai, Antao; Zhao, Peishen; Yang, Dehua; Sexton, Patrick M; Wang, Ming-Wei; Wootten, Denise. (2020). Pharmacological characterization of mono-, dual- and tri-peptidic agonists at GIP and GLP-1 receptors.. Biochemical pharmacology, 177, 114001. https://doi.org/10.1016/j.bcp.2020.114001
MLA
Yuliantie, Elita, et al. "Pharmacological characterization of mono-, dual- and tri-peptidic agonists at GIP and GLP-1 receptors.." Biochemical pharmacology, 2020. https://doi.org/10.1016/j.bcp.2020.114001
RethinkPeptides
RethinkPeptides Research Database. "Pharmacological characterization of mono-, dual- and tri-pep..." RPEP-05228. Retrieved from https://rethinkpeptides.com/research/yuliantie-2020-pharmacological-characterization-of-mono
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.